ABSTRACT
Ferroptosis has gained interest due to it immunogenicity and the higher sensitivity of cancer cells to it. However, it was recently shown that ferroptosis in tumor-associated neutrophils leads to immunosuppression and negatively impacts therapy. Here, we discuss the potential implications of the two sides (friend versus foe) of ferroptosis in cancer immunotherapy.
Acknowledgments
The Cell Death Investigation and Therapy (CDIT) Laboratory led by DVK is supported by FWO-Flanders (G016221N; G043219N), Ghent University BOF (Special Research Fund; BOF/IOP01/O3618, BOF/IOP/2022/033, and BOF23/GOA/029). This project (40007488) has received funding from the FWO and F.R.S.-FNRS under the Excellence of Science (EOS) program. Robin Demuynck (11E3123N) and Iuliia Efimova (11F7723N) are Ph.D. students in the CDIT Laboratory, and they both hold Ph.D. fellowships from FWO-Flanders.
Data availability statement
All data that led to the conclusions in this manuscript have been referenced and all sources have been described.
Disclosure statement
Authors declare no conflict of interests.